Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and Alzheimer disease: Results from the Framingham Heart Study

Archives of Neurology

Volumn 69, Issue 5, 2012, Pages 594-600

  Van Himbergen, Thomas M ^a,d   Beiser, Alexa S ^b,c   Ai, Masumi ^a   Seshadri, Sudha ^b,d   Otokozawa, Seiko ^a   Au, Rhoda ^b,d   Thongtang, Nuntakorn ^a   Wolf, Philip A ^b,d   Schaefer, Ernst J ^a  

^a TUFTS UNIVERSITY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BOSTON UNIVERSITY   (United States)

^d FRAMINGHAM HEART STUDY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E EPSILON4; C REACTIVE PROTEIN; GLUCOSE; GLYCOSYLATED ALBUMIN; INSULIN; PHOSPHOLIPASE A2; UNCLASSIFIED DRUG;

AGE; AGED; ALBUMIN BLOOD LEVEL; ALZHEIMER DISEASE; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DEMENTIA; DIABETES MELLITUS; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; GENOTYPE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HIGH RISK PATIENT; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; RISK REDUCTION; SOCIAL PARTICIPATION; SYSTOLIC BLOOD PRESSURE; WAIST HIP RATIO; WEIGHT CHANGE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADIPONECTIN; AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEINS E; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COHORT STUDIES; DEMENTIA; FEMALE; FLUOROMETRY; HUMANS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SERUM ALBUMIN; SEX FACTORS;

EID: 84860903756     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.670     Document Type: Article

References (46)

1. Bachman DL, Wolf PA, Linn R, et al. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology. 1992; 42(1):115-119.
2. Strittmatter WJ, Weisgraber KH, Huang DY, et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90(17): 8098-8102. (Pubitemid 23260862)
3. Myers RH, Schaefer EJ, Wilson PW, et al. Apolipoprotein E epsilon4 association with dementia in a population-based study: the Framingham study. Neurology. 1996;46(3):673-677.
4. Seshadri S, Beiser AS, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346(7):476-483. (Pubitemid 34441738)
5. Schaefer EJ, Bongard V, Beiser AS, et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol. 2006;63(11):1545-1550. (Pubitemid 44748796)
6. Giordano V, Peluso G, Iannuccelli M, Benatti P, Nicolai R, Calvani M. Systemic and brain metabolic dysfunction as a new paradigm for approaching Alzheimer's dementia. Neurochem Res. 2007;32(4-5):555-567. (Pubitemid 46481288)
7. Whitmer RA. Type 2 diabetes and risk of cognitive impairment and dementia. Curr Neurol Neurosci Rep. 2007;7(5):373-380. (Pubitemid 47422778)
8. Watson GS, Craft S. Insulin resistance, inflammation, and cognition in Alzheimer's disease: lessons for multiple sclerosis. J Neurol Sci. 2006;245(1-2): 21-33. (Pubitemid 43775944)
9. Biessels GJ, Kappelle LJ; Utrecht Diabetic Encephalopathy Study Group. Increased risk of Alzheimer's disease in type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? Biochem Soc Trans. 2005;33(pt 5): 1041-1044. (Pubitemid 41659109)
10. Luchsinger JA, Gustafson DR. Adiposity, type 2 diabetes, and Alzheimer's disease. J Alzheimers Dis. 2009;16(4):693-704.
11. van Oijen M, van der Meer IM, Hofman A, Witteman JCM, Koudstaal PJ, Breteler MMB. Lipoprotein-associated phospholipase A2 is associated with risk of dementia. Ann Neurol. 2006;59(1):139-144. (Pubitemid 43042880)
12. Yaffe K, Lindquist K, Penninx BW, et al. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology. 2003;61(1): 76-80. (Pubitemid 36818750)
13. Roberts RO, Geda YE, Knopman DS, et al. Association of C-reactive protein with mild cognitive impairment. Alzheimers Dement. 2009;5(5):398-405.
14. Schuitemaker A, Dik MG, Veerhuis R, et al. Inflammatory markers in AD and MCI patients with different biomarker profiles. Neurobiol Aging. 2009;30(11):1885-1889.
15. Noble JM, Manly JJ, Schupf N, Tang MX, Mayeux R, Luchsinger JA. Association of C-reactive protein with cognitive impairment. Arch Neurol. 2010;67(1):87-92.
16. Engelhart MJ, Geerlings MI, Meijer J, et al. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study. Arch Neurol. 2004;61(5):668-672. (Pubitemid 38637682)
17. Kravitz BA, Corrada MM, Kawas CH. High levels of serum C-reactive protein are associated with greater risk of all-cause mortality, but not dementia, in the oldest-old: results from the 90+ Study. J Am Geriatr Soc. 2009;57(4):641-646.
18. Dik MG, Jonker C, Hack CE, Smit JH, Comijs HC, Eikelenboom P. Serum inflammatory proteins and cognitive decline in older persons. Neurology. 2005;64 (8):1371-1377. (Pubitemid 40570504)
19. Tan ZS, Beiser AS, Vasan RS, et al. Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology. 2007;68(22):1902-1908. (Pubitemid 46848622)
20. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116(7):1784-1792. (Pubitemid 44033298)
21. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2009;302(2):179-188.
22. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003;423(6941):762-769. (Pubitemid 36735700)
23. Laughlin GA, Barrett-Connor E, May S, Langenberg C. Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. Am J Epidemiol. 2007;165(2):164-174. (Pubitemid 46096378)
24. Wannamethee SG, Whincup PH, Lennon L, Sattar N. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med. 2007;167(14):1510-1517. (Pubitemid 47124181)
25. Debette S, Beiser A, Hoffmann U, et al. Visceral fat is associated with lower brain volume in healthy middle-aged adults. Ann Neurol. 2010;68(2):136-144.
26. Lieb W, Beiser AS, Vasan RS, et al. Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. JAMA. 2009;302 (23):2565-2572.
27. Dawber TR. The Framingham Study: the Epidemiology of Atherosclerotic Disease. Cambridge, MA: Harvard University Press; 1980.
28. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-198.
29. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
30. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-944.
31. Seshadri S, Wolf PA, Beiser AS, et al. Association of plasma total homocysteine levels with subclinical brain injury: cerebral volumes, white matter hyperintensity, and silent brain infarcts at volumetric magnetic resonance imaging in the Framingham Offspring Study. Arch Neurol. 2008;65(5):642-649. (Pubitemid 351679660)
32. Kamei T, Tuji N, Taketani K, Nakamoto M. Evaluation and clinical significance of latex immunoassay (LIA) of insulin using the routine biochemical autoanalyzer. Japanese Journal of Clinical Chemistry. 2006;35(1):48-53.
33. Akomolafe A, Beiser AS, Meigs JB, et al. Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. Arch Neurol. 2006; 63(11):1551-1555. (Pubitemid 44748797)
34. Kouzuma T, Usami T, Yamakoshi M, Takahashi M, Imamura S. An enzymatic method for the measurement of glycated albumin in biological samples. Clin Chim Acta. 2002;324(1-2):61-71. (Pubitemid 35245496)
35. Rawlins ML, La'ulu SL, Moon N, Roberts WL. Performance characteristics of an immunoturbidimetric assay for lipoprotein-associated phospholipase A2. Clin Chim Acta. 2009;406(1-2):66-70.
36. Nishimura A, Sawai T. Determination of adiponectin in serum using a latex particle-enhanced turbidimetric immunoassay with an automated analyzer. Clin Chim Acta. 2006;371(1-2):163-168. (Pubitemid 44162913)
37. Haan MN, Aiello AE, West NA, Jagust WJ. C-reactive protein and rate of dementia in carriers and non carriers of apolipoprotein APOE4 genotype. Neurobiol Aging. 2008;29(12):1774-1782.
38. Une K, Takei YA, Tomita N, et al. Adiponectin in plasma and cerebrospinal fluid in MCI and Alzheimer's disease. Eur J Neurol. 2011;18(7):1006-1009.
39. Sattar N, Nelson SM. Adiponectin, diabetes, and coronary heart disease in older persons: unraveling the paradox. J Clin Endocrinol Metab. 2008;93(9):3299-3301.
40. Wedick NM, Barrett-Connor E, Knoke JD, Wingard DL. The relationship between weight loss and all-cause mortality in older men and women with and without diabetes mellitus: the Rancho Bernardo study. J Am Geriatr Soc. 2002;50(11): 1810-1815. (Pubitemid 35291724)
41. Roubenoff R, Parise H, Payette HA, et al. Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: the Framingham Heart Study. Am J Med. 2003;115(6):429-435. (Pubitemid 37237554)
42. Vasseur F, Helbecque N, Dina C, et al. Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. Hum Mol Genet. 2002;11(21):2607-2614. (Pubitemid 35174690)
43. Hara K, Boutin P, Mori Y, et al. Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes. 2002;51(2):536-540. (Pubitemid 34764814)
44. Xu A, Chan KW, Hoo RLC, et al. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem. 2005;280(18):18073-18080. (Pubitemid 41389052)
45. Nishizawa H, Shimomura I, Kishida K, et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes. 2002;51 (9):2734-2741. (Pubitemid 34970926)
46. Kamogawa K, Kohara K, Tabara Y, et al. Abdominal fat, adipose-derived hormones and mild cognitive impairment: the J-SHIPP study. Dement Geriatr Cogn Disord. 2010;30(5):432-439.